Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | MLYCD | O95822 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23675251 | 0.98 | HPGD (0.71) | HPGDALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4620335 | 0.96 | HPGD (0.73) | HPGDALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8658563 | 0.92 | HPGD (0.68) | HPGDALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4622409 | 0.89 | HPGD (0.64) | HPGDALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL17559346 | 0.86 | HPGD (0.61) | HPGDALDH1A1KDM4EKMT2AGPR183 | |
| SCHEMBL17559372 | 0.86 | HPGD (0.61) | HPGDALDH1A1KMT2AGPR183 | |
| SCHEMBL64495 | 0.86 | HPGD (0.78) | HPGDALDH1A1NPC1KDM4EMEN1 | |
| SCHEMBL17559469 | 0.86 | HPGD (0.61) | HPGDALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL7422569 | 0.84 | HPGD (0.74) | HPGDALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL16845194 | 0.84 | HPGD (0.56) | HPGDALDH1A1RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110759889-B | 2-aryl amido substituted thiophene imide ester compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2022-05-20 | — | — | CN | disclosed |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
| CN-110759889-A | 2-aryl amido substituted thiophene imide ester compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2020-02-07 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-7396844-B1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-6825181-B1 | ORALLY ADMINISTRATED TO EXHIBIT A STRONG ANTICOAGULANT EFFECT BY INHIBITING ACTIVATED BLOOD- COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1065200-A1 | AMINOISOQUINOLINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | HPGD 3242/4885ALDH1A1 4310/4885RAB9A 3871/4885 |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | HPGD 3353/4885ALDH1A1 3784/4885RAB9A 3199/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | HPGD 1610/4885ALDH1A1 3430/4885RAB9A 3368/4885 |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | TLR1, TLR4, TLR2 | HPGD 3242/4885ALDH1A1 3696/4885RAB9A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.